Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802793 | 1.00 | KCNH2 (0.40) | KCNH2CYP19A1MEN1KMT2APRMT5 | |
| SCHEMBL4802813 | 1.00 | KCNH2 (0.40) | KCNH2CYP19A1MEN1KMT2APRMT5 | |
| SCHEMBL3290825 | 0.95 | KCNH2 (0.42) | KCNH2CYP19A1PRMT5WDR77ADRB3 | |
| SCHEMBL3290827 | 0.95 | KCNH2 (0.42) | KCNH2CYP19A1PRMT5WDR77ADRB3 | |
| SCHEMBL4804580 | 0.95 | KCNH2 (0.40) | KCNH2CYP19A1PRMT5WDR77ADRB3 | |
| SCHEMBL4804569 | 0.95 | KCNH2 (0.40) | KCNH2CYP19A1PRMT5WDR77ADRB3 | |
| SCHEMBL4804593 | 0.95 | KCNH2 (0.40) | KCNH2CYP19A1PRMT5WDR77ADRB3 | |
| SCHEMBL3576131 | 0.93 | MRGPRX4 (0.40) | KCNH2PRMT5WDR77ADRB3ABCB1 | |
| SCHEMBL3576133 | 0.93 | MRGPRX4 (0.40) | KCNH2PRMT5WDR77ADRB3ABCB1 | |
| SCHEMBL3287770 | 0.92 | KCNH2 (0.40) | KCNH2CYP19A1PRMT5WDR77ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | CHRM1, CHRM2, C1R | KCNH2 905/4885CYP19A1 390/4885MEN1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.